Publications

  • Email
  • Help

This page lists the publications authored by staff and experts of the European Medicines Agency.

Access to the full texts of the publications may be restricted to people with an individual or institutional subscription to the journal. For more information on a particular publication, contact the corresponding author.

Jump to year

2016

PublicationCorresponding author
Eichler H.G., Hurts H., Broich K., Rasi G., Drug Regulation and Pricing - Can Regulators Influence Affordability?, N Engl J Med, Vol. 374, pp. 1807-1809. doi: 10.1056/NEJMp1601294.hans-georg.eichler@ema.europa.eu
Egger G.F., Wharton G.T., Malli S., Temeck J., Murphy M.D., Tomasi P., A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA from 2007-2013, Therapeutic Innovation & Regulatory Science, doi: 10.1177/2168479016646809gunter.egger@ema.europa.eu
Goedecke T., Ord K., Newbould V., Brosch S., Arlett P., Medication Errors: New EU Good Practice Guide on Risk Minimisation and Error Prevention, Drug Saf. 2016 Mar 3. doi: 10.1007/s40264-016-0410-4Thomas.Goedecke@ema.europa.eu
Gupta A., Mathad J. S., Abdel-Rahman S. M., Albano J. D., Botgros R., Brown V., Browning R. S., Dawson L., Dooley K. E., Gnanashanmugam D., Grinsztejn B., Hernandez-Diaz S., Jean-Philippe P., Kim P., Lyerly A. D., Mirochnick M., Mofenson L. M., Montepiedra G., Piper J., Sahin L., Savic R., Smith B., Spiegel H., Swaminathan S., Watts D. H., White A., Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel, Clin Infect Dis. doi: 10.1093/cid/civ991.radu.botgros@ema.europa.eu
Gravanis I., Tzogani K., van Hennik P., de Graeff P., Schmitt P., Mueller-Berghaus J., Salmonson T., Gisselbrecht C., Laane E., Bergmann L., Pignatti F., The European Medicines Agency review of brentuximab vedotin (Adcetris) for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma, Oncologist, Vol. 21(1), pp. 102-9.iordanis.gravanis@ema.europa.eu
Maciá-Martínez M.A., de Abajo F. J., Roberts G., Slattery J., Thakrar B., Wisniewski A. F., An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies, Drug Saf., Vol. 39(1), pp. 29-43.jim.slattery@ema.europa.eu
Martinalbo J., Bowen D., Camarero J., Chapelin M., Démolis P., Foggi P., Jonsson B., Llinares J., Moreau A., O'Connor D., Oliveira J., Vamvakas S., Pignatti F., Early market access of cancer drugs in the EU, Ann Oncol., Vol. 27(1).jorge.martinalbo@ema.europa.eu
Mazzaglia G., Mol P., Drug Utilization research and risk management, in Elseviers M. et al., Drug Utilization Research - Methods and Applications, Wiley-Blackwell, May 2016,  pp. 392-398.-
Meeker-O'Connell A., Glessner C., Behm M., Mulinde J., Roach N., Sweeney F., Tenaerts P., Landray M. J., Enhancing clinical evidence by proactively building quality into clinical trials, Clin Trials., doi: 1740774516643491fergus.sweeney@ema.europa.eu
Nair H., Ramilo O., Eichler I., Pelfrene E., Mejias A., Polack F. P., Pouwels K. B., Langley J. M., Nunes M., Van der Maas N., Kragten–Tabatabaie L., Baraldi E., Heikkinen T., Fauroux B., Sharland M., Park C., Manzoni P., Papadopoulos N. G., Martinón–Torres F., Stein R., Bont L., in collaboration with Respiratory Syncytial Virus Network (ReSViNET), Harmonization of RSV therapeutics – from design to performance, J. of Global Health,  Vol. 6(1):010205eric.pelfrene@ema.europa.eu
Papathanasiou P., Brassart L., Blake P., Hart A., Whitbread L., Pembrey R., Kieffer J., Transparency in drug regulation: public assessment reports in Europe and Australia, Drug Discovery Today, doi: 10.1016/j.drudis.2016.06.025.jill.kieffer@ema.europa.eu
Pearson A. D., Herold R., Rousseau R., Copland C., Bradley-Garelik B., Binner D., Capdeville R., Caron H., Carleer J., Chesler L., Geoerger B., Kearns P., Marshall L. V., Pfister S. M., Schleiermacher G., Skolnik J., Spadoni C., Sterba J., van den Berg H., Uttenreuther-Fischer M., Witt O., Norga K., Vassal G., Members of Working Group 1 of the Paediatric Platform of ACCELERATE; Implementation of mechanism of action biology-driven early drug development for children with cancer, Eur J Cancer, Vol 62, pp. 124-131ralf.herold@ema.europa.eu
Pelfrene E., Willebrand E., Cavaleiro Sanches A., Sebris Z., Cavaleri M., Bacteriophage therapy: a regulatory perspective, J. Antimicrob. Chemother.,
doi: 10.1093/jac/dkw083.
eric.pelfrene@ema.europa.eu
Pinheiro L., Blake K., Januskiene J., Yue Q. Y., Arlett P., Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance, doi: 10.1002/pds.3998.luis.pinheiro@ema.europa.eu
Postmus D., Mavris M., Hillege H.L., Salmonson T., Ryll B., Plate A., Moulon I., Eichler H.G., Bere N., Pignatti F., Incorporating Patient Preferences Into Drug Development and Regulatory Decision Making: Results From a Quantitative Pilot Study With Cancer Patients, Carers, and Regulators, Clin Pharmacol Ther., Vol. 99(5), pp. 548-54.d.postmus@umcg.nl
Saint-Raymond A., Pelle B., Zaccaria C., Sennwitz M., Branch S., Usage of unpublished paediatric data, Arch Dis Child., Vol. 101(1), pp. 81-4.agnes.saint-raymond@ema.europa.eu
Seabroke S., Candore G., Juhlin K., Quarcoo N., Wisniewski A., Arani R., Painter J., Tregunno P., Noren N., Slattery J., Innovation of medical products: the evolution of regulatory science, research and education, Drug Saf., Vol. 39(4), pp. 355-64.jim.slattery@ema.europa.eu
Slattery J., Measuring Signal Detection Performance: Can We Trust Negative Controls and Do We Need Them?, Vol. 39(5), pp. 371-3.jim.slattery@ema.europa.eu
Spindler P., Bach K. F., Schmiegelow M., Bedlington N., Eichler H. G., Innovation of medical products: the evolution of regulatory science, research and education, Therapeutic Innovation & Regulatory Science, Vol. 50(1), pp. 44-48.hans-georg.eichler@ema.europa.eu
Straub V.,  Balabanov P., Bushby K., Ensini M., Goemans N., De Luca A., Pereda A., Hemmings R., Campion G., Kaye E., Arechavala-Gomeza V., Goyenvalle A., Niks E., Velldhuizen O., Furlong P., Stoyanova-Beninska V., Wood M. J., Johnson A., Mercuri E., Muntoni F., Sepodes B., Haas M., Vroom E., Aartsma-Rus A.. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy,The Lancet Neurology, Vol. 15(8), pp. 882–890.pavel.balabanov@ema.europa.eu
Tafuri G., Pagnini M., Moseley J., Massari M., Petavy F., Behring A., Catalan A., Gajraj E., Hedberg N., Obach M., Osipenko L., Russo P., Van De Casteele M., Zebedin EM., Rasi G., Vamvakas S., How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice, Br J Clin Pharmacol, doi: 10.1111/bcp.13023.giovanni.tafuri@ema.europa.eu
Tamborlane W.V., Haymond M.W., Dunger D., Shankar R., Gubitosi-Klug R., Bethin K., Karres J., Tomasi P., Libman I., Hale P.H., Portman R., Klingensmith G., Reed M., Blumer J., Giacoia G., Expanding Treatment Options for Youth with Type 2 Diabetes: Current Problems and Proposed Solutions, Diabetes Care, Vol. 39(3), pp. 323–329.janina.karres@ema.europa.eu
Van Riet-Nales D.A., Hussain N., Sundberg K.A., Eggenschwyler D., Ferris C., Robert J.L., Cerreta F., Regulatory incentives to ensure better medicines for older people: from ICH E7 to the EMA reflection paper on quality aspects, Int J Pharm. 2016 May 2. pii: S0378-5173(16)30367-2.da.v.riet@cbg-meb.nl

Vicini P., Fields O., Lai E., Litwack E. D., Martin A. M., Morgan T. M., Pacanowski M. A., Papaluca M., Perez O. D., Ringel M. S., Robson M., Sakul H., Vockley J., Zaks T., Dolsten M., Søgaard M., Precision Medicine in the Age of Big Data: The Present and Future Role of Large Scale Unbiased Sequencing in Drug Discovery and Development, Clin Pharmacol Ther., Vol. 99(2), pp. 198-207.

marisa.papaluca@ema.europa.eu
Wisniewski A.F.Z., Bate A., Bousquet C., Brueckner A., Candore G., Juhlin K., Marcia-Martinez M.A., Manlik K., Quarcoo N., Seabroke S., Slattery J., Southworth H., Thakrar B., Tregunno P., Van Holle L., Kayser M., Noren G.N., Good Signal Detection Practices: Evidence from IMI PROTECT, Drug Safety, doi: 10.1007/s40264-016-0405-1.jim.slattery@ema.europa.eu

 

2015

Back to top

PublicationCorresponding author
Bahri P., Dodoo A. N., Edwards B. D., Edwards I. R., Fermont I., Hagemann U., Hartigan-Go K., Hugman B., Mol P. G., 'The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance', Drug Saf., Vol. 38(7), pp. 621-627priya.bahri@ema.europa.eu
Bartlett J. A., Brewster M., Brown P., Cabral-Lilly D., Cruz C. N., David R., Eickhoff W. M., Haubenreisser S., Jacobs A., Malinoski F., Morefield E., Nalubola R., Prud'homme R. K., Sadrieh N., Sayes C. M., Shahbazian H., Subbarao N., Tamarkin L., Tyner K., Uppoor R., Whittaker-Caulk M., Zamboni W., 'Summary report of PQRI workshop on nanomaterial in drug products: current experience and management of potential risks', The AAPS Journal, Vol. 17(1), pp. 44-64.celia.cruz@fda.hhs.gov
Blind E., de Graeff P. A., Meurs I., Holtkamp F., Baczynska A., Janssen H., The European Medicines Agency’s approval of proprotein convertase subtilisin/kexin type 9 inhibitors, Eur Heart J. pii: ehv673.eberhard.blind@ema.europa.eu
Bonelli M., Di Giuseppe F., Beken S., 'Impact analysis of ICH S9 on non-clinical development of anticancer drugs', Regul Toxicol Pharmacol., Vol. 73(1), pp. 361-366milton.bonelli@ema.europa.eu
Both L., Botgros R., Cavaleri M., Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012, Euro Surveill., Vol. 20(34).leoboth@gmx.de
Butlen-Ducuing F., Zienowicz M., Pétavy F., Haas M., Salmonson T., Eichler H.G., Rasi G., European regulatory experience with drugs for central nervous system disorders, Nat Rev Drug Discov., Vol14(2), pp. 89-90.florence.butlen@ema.europa.eu
Catry B., Cavaleri M., Baptiste K., Grave K., Grein K., Holm A., Jukes H., Liebana E., Lopez Navas A., Mackay D., Magiorakos A. P., Moreno Romo M. A., Moulin G., Muñoz Madero C., Matias Ferreira Pomba M. C., Powell M., Pyörälä S., Rantala M., Ružauskas M., Sanders P., Teale C., Threlfall E. J., Törneke K., van Duijkeren E., Torren Edo J., Use of colistin-containing products in animals within the European Union and European Economic Area (EU/EEA): development of resistance and possible impact on human and animal health, Int J Antimicrob Agents, Vol 46(3), pp. 297-306.jordi.torren@ema.europa.eu
Cohen J., Vincent J. L., Adhikari N. K. J., Machado F. R. , Angus D. C., Calandra T., Jaton K.,  Giulieri S., Delaloye J., Opal S., Tracey K.,  van der Poll T., Pelfrene E., 'Sepsis: a roadmap for future research', Lancet Infect Dis., doi: http://dx.doi.org/10.1016/S1473-3099(15)70112-Xeric.pelfrene@ema.europa.eu
Dal Pan G. J., Arlett P. R., ‘The US Food and Drug Administration-European Medicines Agency collaboration in pharmacovigilance: common objectives and common challenges’, Drug Saf., Vol. 38, pp. 13-15.peter.arlett@ema.europa.eu
Dodt J., Hubbard A. R., Wicks S. J., Gray E., Neugebauer B., Charton E., Silvester G., 'Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators', Haemophilia, doi: 10.1111/hae.12634.glenda.silvester@ema.europa.eu
Ehmann F., Caneva L., Prasad K., Paulmichl M., Maliepaard M., Llerena A., Ingelman-Sundberg M., Papaluca-Amati M., 'Pharmacogenomic information in drug labels: European Medicines Agency perspective', Br J Clin Pharmacol., doi:10.1038/tpj.2014.86.falk.ehmann@ema.europa.eu
Ehmann F., Papaluca M., Di Giuseppe F., Pani L., Eskova A., Manolis E., Herold R., 'Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union', Expert Opin Pharmacother, Vol.16(6), pp. 903-11.falk.ehmann@ema.europa.eu
Eichler H. G., Baird L., Barker R., Bloechl-Daum B., Børlum-Kristensen F., Brown J., Chua R., Del Signore S., Dugan U., Ferguson J., Garner S., Goettsch W., Haigh J., Honig P., Hoos A., Huckle P., Kondo T., Le Cam Y., Leufkens H., Lim R., Longson C., Lumpkin M., Maraganore J., O'Rourke B., Oye K., Pezalla E., Pignatti F., Raine J., Rasi G., Salmonson T., Samaha D., Schneeweiss S., Siviero P., Skinner M., Teagarden J., Tominaga T., Trusheim M., Tunis S., Unger T., Vamvakas S., Hirsch G., 'From adaptive licensing to adaptive pathways: delivering a flexible life span approach to bring new drugs to patients', Clin Pharmacol Ther., Vol. 97(3), pp. 234-46.hans-georg.eichler@ema.europa.eu
Eichler H.G, Thomson A., Eichler I., Schneeweiss S., 'Assessing the relative efficacy of new drugs: an emerging opportunity', Nature Reviews Drug Discovery, Vol. 14, pp. 443–444.hans-georg.eichler@ema.europa.eu
Goldman M., Seigneuret N., Eichler H. G., 'The Innovative Medicines Initiative: An engine for regulatory science', Nat Rev Drug Discov., Vol. 14(1), pp.1-2hans-georg.eichler@ema.europa.eu
Gupta A., Mathad J.S., Abdel-Rahman S.M., Albano J.D., Botgros R., Brown V., Browning R.S., Dawson L., Dooley K.E., Gnanashanmugam D., Grinsztejn B., Hernandez-Diaz S., Jean-Philippe P., Kim P., Lyerly A.D., Mirochnick M., Mofenson L.M., Montepiedra G., Piper J., Sahin L., Savic R., Smith B., Spiegel H., Swaminathan S., Watts D.H., White A., 'Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel', Clin Infect Dis. 2015 Dec 9. pii: civ991.-
Haas M., Vlcek V., Balabanov P., Salmonson T., Bakchine S., Markey G., Weise M., Schlosser-Weber G., Brohmann H., Yerro C. P., Mendizabal M. R., Stoyanova-Beninska V., Hillege H. L., 'The European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Neuromuscul Disord. Vol. 25(1), pp.5-13manuel.haas@ema.europa.eu
Hanaizi Z., Flores B., Hemmings R., Camarero J., Sancho-Lopez A., Salmonson T., Gisselbrecht C., Laane E., Pignatti F.,' The European Medicines Agency review of pomalidomide for the treatment of adult patients with multiple myeloma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Oncologist, Vol. 20(3), pp. 329-334.zahra.hanaizi@ema.europa.eu
Haubenreisser s., Harvey-Allchurch M., Chapter 3 - The European Medicines Agency and the Regulation of Medicines in the European Union, Food and Drug Regulation in an Era of Globalised Marekts, pp. 25-36.sabine.haubenreisser@ema.europa.eu
Hofer M.P., Jakobsson C., Zafiropoulos N., Vamvakas S., Vetter T., Regnstrom J., Hemmings R.J., Regulatory watch: Impact of scientific advice from the European Medicines Agency, Nature Reviews Drug Discovery, Vol 14(5), pp. 302-303.jan.regnstrom@ema.europa.eu
Klug B., Celis P., Ruepp R., Robertson J S., EU regulatory guidelines for the clinical evaluation of adjuvants, Clin Res Pr Drug Regul Aff, doi:10.3109/10601333.2015.1001899robin.ruepp@ema.europa.eu
Koenig F., Slattery S., Groves T., Lang T., Benjamini Y., Day S., Bauer P., and Posch M., Sharing clinical trial data on patient level: Opportunities and challenges, Biometrical Journal 57, 8-26, (2015) [bib]Franz.Koenig@meduniwien.ac.at
Krause P. R., Cavelari M., Coleman G., Gruber M. F., Approaches to Demonstration of Ebola Virus Vaccine Efficacy, Lancet, Vo. 15(6), pp. 615-746.marco.cavaleri@ema.europa.eu
Loth E., Spooren W., Ham L. M., Isaac M. B., Auriche-Benichou C., Banaschewski T., Baron-Cohen S., Broich K., Bölte S., Bourgeron T., Charman T., Collier D., de Andres-Trelles F., Durston S., Ecker C., Elferink A., Haberkamp M., Hemmings R., Johnson M. H., Jones E. J., Khwaja O. S., Lenton S., Mason L., Mantua V., Meyer-Lindenberg A., Lombardo M. V., O'Dwyer L., Okamoto K., Pandina G. J., Pani L., Persico A. M., Simonoff E., Tauscher-Wisniewski S., Llinares-Garcia J., Vamvakas S., Williams S., Buitelaar J. K., Murphy D. G., Identification and Validation of Biomarkers for Autism Spectrum Disorders, Nat Rev Drug Discov. Vol 15(1), pp. 70-3.maria.isaac@ema.europa.eu
Luciani F., Galluzzo S., Gaggioli A., Kruse N. A., Venneugues P., Schneider C. K., Pini C., Melchiorri D., Implementing quality by design for biotech products: are regulators on track?, Vol 7(3), pp. 451-455s.galluzzo@aifa.gov.it
Luigetti R., Cooke E., Cuddy B., Goux S., Rees I., GMP Oversight of Medicines Manufacturers in the European Union, PDA Letterriccardo.luigetti@ema.europa.eu
Murray S., McKenna L., Pelfrene E., Botgros R., Accelerating clinical drug development for children with tuberculosis, International Journal of Tuberculosis and Lung Disease., 2015 Dec;19 Suppl 1, pp. 69-74.eric.pelfrene@ema.europa.eu
Nachman S., Ahmed A., Amanullah F., Becerra M. C., Botgros R., Brigden G., Browning R., Gardiner E., Hafner R., Hesseling A., How C., Jean-Philippe P., Lessem E., Makhene M., Mbelle N., Marais B., McIlleron H., McNeeley D. F., Mendel C., Murray S., Navarro E., Anyalechi E. G., Porcalla A. R., Powell C., Powell M., Rigaud M, Rouzier V., Samson P., Schaaf H. S., Shah S., Starke J., Swaminathan S., Wobudeya E., Worrell C., Towards early inclusion of children in tuberculosis drugs trials: a consensus statement, Lancet Infect Dis., Vol. 15(6), pp. 711–720.-
Offringa M., Davis J.M., Turner M.A., Ward R., Bax R., Maldonado S., Sinha V., McCune S.K., Zajicek A., Benjamin D.K., Bucci-Rechtsweg C., Nelson R.M., Applying Regulatory Science to Develop Safe and Effective Medicines for Neonates: Report of the US Food and Drug Administration First Annual Neonatal Scientific Workshop, October 28-29, 2014, Therapeutic Innovation & Regulatory Science, 7 August 2015ralph.bax@ema.europa.eu
Oye K.A., Pearson M., Eichler H.G., Mullin T., Hoos A., Managing uncertainty in drug development and use informed regulation: Enhancing adaptability and flexibility in pharmaceuticals regulation. In: Improving Risk Regulation, International Risk Governance Council (IRGC). Lausanne: IRGC, 2015 (63-80).hans-georg.eichler@ema.europa.eu
Pacurariu A.C., Straus S.M., Trifirò G., Schuemie M.J., Gini R., Herings R., Mazzaglia G., Picelli G., Scotti L., Pedersen L., Arlett P., Van der Lei J., Sturkenboom M.C., Coloma P.M., Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection, Drug Saf., doi:10.​1007/​s40264-015-0341-5, doi:10.1586/17512433.2015.1028918a.pacurariu@erasmusmc.nl
Papaluca M., Grecoa M., Tognana E., Ehmann F., Saint-Raymond A., White spots in pharmaceutical pipelines–EMA identifies potential areas of unmet medical needs, Expert Review of Clinical Pharmacology, Vol.8, Issue 3, 2015-
Pelfrene E., Pinheiro M. H., Cavaleri M., 'Artemisinin-based combination therapy in the treatment of uncomplicated malaria: review of recent regulatory experience at the European Medicines Agency', Int Health, doi: 10.1093/inthealth/ihv017.eric.pelfrene@ema.europa.eu
Pignatti F., Ashby D., Brass E. P., Eichler H. G., Frey P., Hillege H. L., Hori A., Levitan B., Liberti L., Löfstedt R. E., McAuslane N., Micaleff A., Noel R. A., Postmus D., Renn O., Sabourin B. J., Salmonson T., Walker S., Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions, Vol. 98(5), pp. 522-33.francesco.pignatti@ema.europa.eu
Rottenkolber M., Voogd E., van Dijk L., Primatesta P., Becker C., Schlienger R., de Groot M. C., Alvarez Y., Durand J., Slattery J., Afonso A., Requena G., Gil M., Alvarez A., Hesse U., Gerlach R., Hasford J., Fischer R., Klungel O. H., Schmiedl S., 'Time trends of period prevalence rates of patients with inhaled long-acting Beta-2-agonists-containing prescriptions: a European comparative database study', PLoS One, Vol.10(2):e0117628.yalvarezg@gmail.com
Salmikangas P., Menezes-Ferreira M., Reischl I., Tsiftsoglou A., Kyselovic J., Borg J. J., Ruiz S., Flory E., Trouvin J. H., Celis P., Ancans J., Timon M., Pante G., Sladowski D., Lipnik-Stangelj M., Schneider C. K., 'Manufacturing, characterisation and control of cell-based medicinal products: challenging paradigms towards commercial use', Regen. Med., Vol. 10(1), pp. 65-78.

patrick.celis@ema.europa.eu

Samardzic J., Turner M.A., Bax R., Allegaert K., Neonatal Medicines Research: Challenges and Opportunities, Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1041-52ralph.bax@ema.europa.eu
Segec A., Keller-Stanislawski B., Vermeer N.S., Macchiarulo C., Straus S.M., Hidalgo-Simon A., De Bruin M.L., Strategy in Regulatory Decision-Making for Management of Progressive Multifocal Leukoencephalopathy, Clinical Pharmacology & Therapeutics, Vol. 98(5), pp. 502-505.andrej.segec@ema.europa.eu
Torneke K., Torren-Edo J., Grave K., Mackay D. K., The management of risk arising from the use of antimicrobials in veterinary medicine in EU/EEA countries – a review, J Vet Pharmacol Ther. doi: 10.1111/jvp.12226.jordi.torren@ema.europa.eu
Torren E. J., Grave K., Mackay D., '“One Health”: the regulation and consumption of antimicrobials for animal use in the EU', IAHJ, Vol. 2, pp.14-16.jordi.torren@ema.europa.eu
Vermeer N.S., Straus S.M.J.M., Mantel-Teeuwisse A.K., Hidalgo-Simon A., Egberts A.C.G., Leufkens H.G.M., De Bruin M.L., Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab, Clinical Pharmacology and Therapeutics, Vol. 98(5), pp. 542-550.ana.hidalgo-simon@ema.europa.eu
Walton M. K., Powers J. H. 3rd, Hobart J., Patrick D., Marquis P., Vamvakas S., Isaac M., Molsen E., Cano S., Burke L. B., Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force, Value Health Vol18, pp. 741-52.maria.isaac@ema.europa.eu

 

2014

Back to top

PublicationCorresponding author
Aartsma-Rus A., Ferlini A., Goemans N., Pasmooij A. M., Wells D. J., Bushby K., Vroom E., Balabanov P., 'Translational and regulatory challenges for exon skipping therapies', Human Gene Therapy, Vol. 25(10), pp. 885-92.pavel.balabanov@ema.europa.eu
Abbing-Karahagopian V., Huerta C., Souverein P. C., de Abajo F., Leufkens H. G., Slattery J., Alvarez Y., Miret M., Gil M., Oliva B., Hesse U., Requena G., de Vries F., Rottenkolber M., Schmiedl S., Reynolds R., Schlienger R. G., de Groot M. C., Klungel O. H., van Staa T. P., van Dijk L., Egberts A. C., Gardarsdottir H., De Bruin M. L., 'Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications', Eur J Clin Pharmacol, Vol. 70(7), pp. 849-857.m.l.debruin@uu.nl
Abbing-Karahagopian V., Kurz X., de Vries F., van Staa T. P., Alvarez Y., Hesse U., Hasford J., van Dijk L., de Abajo F. J., Weil J. G., Grimaldi-Bensouda L., Egberts A. C., Reynolds R. F., Klungel O. H., 'Bridging differences in outcomes of pharmacoepidemiological studies: Design and first results of the Protect project', Curr Clin Pharmacol, Vol 9, pp. 130-138.o.h.klungel@uu.nl
Arlett P., Portier G., de Lisa R., Blake K., Wathion N., Dogne J. M., Spooner A., Raine J., Rasi G., 'Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee', Nat Rev Drug Discov, Vol. 13(5), pp. 395-397.peter.arlett@ema.europa.eu
Arlett .P, Postigo R., Janssen H., Spooner A., 'Periodic Benefit-Risk Evaluation Report: A European Union Regulatory Perspective'. Pharmaceutical Medicine', Vol. 28(6), pp. 309-315.rodrigo.postigo@ema.europa.eu
Arlett P., Sarac S. B., Thomson A., Davies C., Teixeira T., Blake K. V., Stenver D., 'The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac', Pharmacoepidemiol Drug Saf, Vol. 23(4), pp. 431-434.peter.arlett@ema.europa.eu
Baird L. G., Banken R., Eichler H. G., Kristensen F. B., Lee D. K., Lim J. C., Lim R., Longson C., Pezalla E., Salmonson T., Samaha D., Tunis S., Woodcock J., Hirsch G., 'Accelerated access to innovative medicines for patients in need', Clin Pharmacol Ther, Vol. 96(5), pp. 559–571.lbaird@mit.edu
Balabanov P., Haas M., Elferink A., Bakchine S., Broich K., 'Addressing the regulatory and scientific challenges in multiple sclerosis - a statement from the EU regulators', Mult Scler, Vol. 20(10), pp. 1282-1287.pavel.balabanov@ema.europa.eu
Beckmann J., Hagemann U., Bahri P., Bate A., Boyd I. W., Dal Pan G. J., Edwards B. D., Edwards I. R., Hartigan-Go K., Lindquist M., McEwen J., Moride Y., Olsson S., Pal S. N., Soulaymani-Bencheikh R., Tuccori M., Vaca C. P., Wong I. C. K., 'Teaching pharmacovigilance: the WHO-ISoP core elements of a comprehensive modular curriculum', Drug Saf, Vol. 37(10), pp. 743-759.j.beckmann.berlin@web.de
Berntgen M., Gourvil A., Pavlovic M., Goettsch W., Eichler H.-G., Kristensen F. B., 'Improving the contribution of regulatory assessment reports to health technology assessments - a collaboration between the European Medicines Agency and the European Network for Health Technology Assessment', Value in Health, Vol. 17(5), pp. 634-641.michael.berntgen@ema.europa.eu
Blake K. V., Zaccaria C., Domergue F., La Mache E., Saint-Raymond A., Hidalgo-Simon A., 'Comparison between paediatric and adult suspected adverse drug reactions reported to the European Medicines Agency: implications for pharmacovigilance', Pediatric Drugs, Vol. 16(4), pp. 309-319.kevin.blake@ema.europa.eu
Bonini S., Eichler H. G., Wathion N., Rasi G., ‘Transparency and the European Medicines Agency – sharing of clinical trial data’, N Engl J Med, Vol. 371(26), pp. 2452-2455.-
Borg J. J., Tomasi P., Pani L.,  Aislaitner G., Pirozynski M., Leufkens H., Melchiorri D., 'Licensing of generic medicines: are there any challenges left? A pharmaceutical regulatory perspective', Sci Pharm, Vol. 82, pp. 847-856.john-joseph.borg@gov.mt
Butlen-Ducuing F., Zienowicz M., Pétavy F., Haas M., Salmonson T., Eichler H., Rasi G., ‘European regulatory experience with drugs for central nervous system disorders’, Nat Rev Drug Discov, doi: 10.1038/nrd4511.-
Caneva L., Bonelli M., Papaluca-Amati M., Vidal J. M., 'Critical review on the environmental risk assessment of medicinal products for human use in the centralised procedure', Regul Toxicol Pharmacol, Vol. 68(3), pp. 312-316.milton.bonelli@ema.europa.eu
Cerreta F., Temple R., Asahina Y., Connaire C., 'Regulatory activities to address the needs of older patients', J Nutr Health Aging, doi: 10.1007/s12603-014-0494-4.francesca.cerreta@ema.europa.eu
Cortes-Blanco .A, Prieto-Yerro C., Martinez-Lazaro R., Zamora J., Jiménez-Huete A., Haberkamp M., Pohly J., Enzmann H., Zinserling J., Strassmann V., Broich K.. 'Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval', Alzheimers Dement., Vol. 10(5 Suppl), pp. S395-9.cprieto@aemps.es
de Groot M. C., Schuerch M., de Vries F., Hesse U., Oliva B., Gil M., Huerta C., Requena G., de Abajo F., Afonso A. S., Souverein P. C., Alvarez Y., Slattery J., Rottenkolber M., Schmiedl S., Van Dijk L., Schlienger R. G., Reynolds R., Klungel O. H., 'Antiepileptic drug use in seven electronic health record databases in Europe: A methodologic comparison', Epilepsia, Vol. 55(5), pp. 666-673.m.c.h.degroot@uu.nl
Egan A. G., Blind E., Dunder K., de Graeff P. A., Hummer B. T., Bourcier T., Rosebraugh C., 'Pancreatic safety of incretin-based drugs — FDA and EMA assessment', N Engl J Med, Vol. 370(9), pp. 794-797.-
Egger G. F., Manent N., 'Re: Non-publication and delayed publication of randomized trials on vaccines: survey', BMJ, 2014, Vol. 348, g3058.  -
Eichler H. G., Baird L. G., Barker R., Bloechl-Daum B., Børlum-Kristensen F., Brown J., Chua R., Del Signore S., Dugan U., Ferguson J., Garner S., Goettsch W., Haigh J., Honig P., Hoos A., Huckle P., Kondo T., Le Cam Y., Leufkens H., Lim R., Longson C., Lumpkin M., Maraganore J., O'Rourke B., Oye K., Pezalla E., Pignatti F., Raine J., Rasi G., Salmonson T., Samaha D., Schneeweiss S., Siviero P. D., Skinner M., Teagarden J. R., Tominaga T., Trusheim M. R., Tunis S., Unger T. F, Vamvakas S., Hirsch G., 'From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients', Clin Pharmacol Ther, DOI: 10.1002/cpt.59.hans-georg.eichler@ema.europa.eu
Eichler H. G., Oye K., Baird L. G., Abadie E., Brown J., Drum C. L., Ferguson J., Garner S., Honig P., Hukkelhoven M., Lim J. C., Lim R., Lumpkin M. M., Neil G., O'Rourke B. ,Pezalla E., Shoda D., Seyfert-Margolis V., Sigal E. V., Sobotka J., Tan D., Unger T. F., Hirsch G., Adaptive licensing: taking the next step in the evolution of drug approval’, Clin Pharmacol Ther, Vol. 91(3), pp. 426-37.hans-georg.eichler@ema.europa.eu
Franco P., Porta N., Holliday J. D., Willett P., 'The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation', J Cheminform, Vol. 6(1): 5.p.willett@sheffield.ac.uk
Gravanis I., Vleminckx C., Jonsson B., Pignatti F., 'The changing world of oncology dug development: the regulatory bodies’ perspective', Chin Clin Oncol, Vol. 3(2), p. 22.iordanis.gravanis@ema.europa.eu
Grave K., Mackay D., Muller A., Torren-Edo J., 'European Surveillance of Veterinary Antimicrobial Consumption (ESVAC): Establishment of the project and key outputs', Regulatory Rapporteur, Vol. 11(9), pp. 4-9.-
Grave K., Torren-Edo J., Muller A., Greko C., Moulin G., Mackay D., ESVAC Group, 'Variations in the sales and sales patterns of veterinary antimicrobial agents in 25 European countries', J Antimicrob Chemother, Vol. 69(8), pp. 2284-2291.kari.grave@ema.europa.eu
Hampson L. V., Herold R., Posch M., Saperia J., Whitehead A., 'Bridging the gap: A review of dose-investigations in paediatric investigation plans', Br J Clin Pharmacol, Vol. 78(4), pp. 898–907.l.v.hampson@lancaster.ac.uk
Hanaizi Z., Unkrig C., Enzmann H., Camarero J., Sancho-Lopez A., Salmonson T., Gisselbrecht C., Laane E., Pignatti F., 'The European Medicines Agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukaemia: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Oncologist., Vol.19(4), pp. 421-5.zahra.hanaizi@ema.europa.eu
Herold R., Saint-Raymond A., Norga K., 'Too few medicines for children with cancer', JAMA Pediatr., Vol.168(6), p. 583.ralf.herold@ema.europa.eu
Hill D. L., Schwarz A. J., Isaac M., Pani L., Vamvakas S., Hemmings R., Carrillo M. C., Yu P., Sun J., Beckett L., Boccardi M., Brewer J., Brumfield M., Cantillon M., Cole P. E., Fox N., Frisoni G. B., Jack C., Kelleher T., Luo F., Novak G., Maguire P., Meibach R., Patterson P., Bain L., Sampaio C., Raunig D., Soares H., Suhy J., Wang H., Wolz R., Stephenson D., 'Coalition Against Major Diseases / European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease', Alzheimers Dement, Vol. 10(4), pp. 421-429.dstephenson@c-path.org
Kurki P., Bielsky M.C.; Working Party on Similar Biological (Biosimilar) Medicinal Products (BMWP) of Committee for Medicinal Products for Human Use (CHMP), 'Letter to the editor: ECCO position challenged by European drug regulators', J Crohns Colitis. 2014 Mar;8(3):258    
Lincker H., Ziogas C., Carr M., Porta N., Eichler, H. G., 'Regulatory watch: Where do new medicines originate from in the EU?', Nat Rev Drug Discov, Vol. 13(2), pp. 92-93.constantinos.ziogas@ema.europa.eu
Mackay D., Grave K., Muller A., Torren-Edo J., 'Key success factors for surveys of antimicrobial sales and use in the European Union', in proceeding: 'Responsible and prudent use of antimicrobial agents for animals. International solidarity to fight against antimicrobial resistance', OIE Global Conference, Paris, France, 13-15 March 2013, pp. 28-31.-
Mariz S., Tsigkos S., Fregonese L., Aarum S., Dehlink R., Llinares J., Sepodes B., 'The orphan framework as a new opportunity: an expert opinion', Informa healthcare, Vol. 2(11 ), pp. 1181-1186.segundo.mariz@ema.europa.eu
Mentzer D., Desfontaine E., Tomasi P. A., 'The importance and challenge of pediatric trials of hemophilia drugs', Nat Med., doi:10.1038/nm.3546paolo.tomasi@ema.europa.eu
Nofziger C., Papaluca M., Terzic A., Waldman S., Paulmichl M., 'Policies to aid the adoption of personalized medicine', Nat Rev Drug Discov, Vol. 13(3), pp. 159-160.markus.paulmichl@pmu.ac.at
scott.waldman@jefferson.edu
terzic.andre@mayo.edu
Pacurariu A.C., Coloma P. M., van Haren A., Genov G., Sturkenboom M. C., Straus S. M., 'A description of signals during the first 18 months of the EMA Pharmacovigilance Risk Assessment Committee', Drug Saf., Vol. 37(12), pp.1059-66.georgy.genov@ema.europa.eu
Pignatti F., Jonsson B., Blumenthal G., Justice R., 'Assessment of benefits and risks in development of targeted therapies for cancer - The view of regulatory authorities', Mol Oncol., pii: S1574-7891(14)00242-7francesco.pignatti@ema.europa.eu
Peschel W., 'The use of community herbal monographs to facilitate registrations and authorisations of herbal medicinal products in the European Union 2004-2012', J Ethnopharmacol, doi: 10.1016/j.jepwieland.peschel@ema.europa.eu
Pfleiderer M., Trouvin J. H., Brasseur D., Gränstrom M., Shivji R., Mura M., Cavaleri M., 'Brief Report for Vaccine - Summary of knowledge gaps related to quality and efficacy of current influenza vaccines', Vaccine., Vol 32(35), pp. 4586-91.manuela.mura@ema.europa.eu
Pignatti F., Ehmann F., Hemmings R., Jonsson B., Nuebling M., Papaluca-Amati M., Posch M., Rasi G., 'Cancer drug development and the evolving regulatory framework for companion diagnostics in the European Union', Clin Cancer Res. Vol. 20(6), pp.1458-68.francesco.pignatti@ema.europa.eu
Quijano Ruiz B., Desfontaine E., Arenas-López S., Wang S., 'Pediatric formulation issues identified in paediatric investigation plans', Expert Rev Clin Pharmacol, Vol. 7(1), pp. 25-30.emilie.desfontaine@ema.europa.eu
Requena G., Abbing-Karahagopian V., Huerta C., De Bruin M. L., Alvarez Y., Miret M., Hesse U., Gardarsdottir H., Souverein P. C., Slattery J., Schneider C., Rottenkolber M., Schmiedl S., Gil M., De Groot M. C., Bate A., Ruigómez A., García Rodríguez L. A., Johansson S., de Vries F., Montero D., Schlienger R., Reynolds R., Klungel O. H., de Abajo F. J., 'Trends in incidence rates of hip and femur fractures in five European countries, 2003-2009: a comparison using electronic health care records databases', Calcif Tissue Int., Vol. 94(6), pp. 580-9.yalvarezg@gmail.com
Requena G., Abbing-Karahagopian V., Huerta C., De Bruin M. L., Alvarez Y., Miret M., Hesse U., Gardarsdottir H., Souverein P. C., Slattery J., Schneider C., Rottenkolber M., Schmiedl S., Gil M., De Groot M. C., Bate A., Ruigómez A., García Rodríguez L. A., Johansson S., de Vries F., Montero D., Schlienger R., Reynolds R., Klungel O. H., de Abajo F. J., 'Incidence rates and trends of hip/femur fractures in five European countries: comparison using e-healthcare records databases', Calcif Tissue Int, Vol. 94(6), pp. 580-589.francisco.abajo@uah.es
Selker H. P., Oye K. A., Eichler H. G., Stockbridge N. L., Mehta C. R., Kaitin K. I., McElwee N. E., Honig P. K., Erban J. K., D'Agostino R. B. 'A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials', Clin Pharmacol Ther, Vol. 95(2), pp. 147-153.hselker@tuftsmedicalcenter.org
Sun H., Vesely R., Nelson R. M., Taminiau J., Szitanyi P., Isaac M., Klein A., Uzu S., Griebel D., Mulberg A. E., International Inflammatory Bowel Disease Working Group, ‘Steps toward harmonization for clinical development of medicines in pediatric ulcerative colitis-a global scientific discussion, part 2: data extrapolation, trial design, and pharmacokinetics’, J Pediatr Gastroenterol Nutr, Vol. 58(6), pp. 684-688.richard.vesely@ema.europa.eu
Sun H., Vesely R., Taminiau J., Szitanyi P., Papadopoulos E. J., Isaac M., Klein A., Uzu S., Griebel D., Mulberg A. E., International Inflammatory Bowel Disease Working Group, ‘Steps toward harmonization for clinical development of medicines in pediatric ulcerative colitis-a global scientific discussion, part 1: efficacy endpoints and disease outcome assessments’, J Pediatr Gastroenterol Nutr, Vol. 58(6), pp. 679-683.richard.vesely@ema.europa.eu
Tsigkos S., Llinares J., Mariz S., Aarum S., Fregonese L., Dembowska-Baginska B., Elbers R., Evers P., Foltanova T., Lhoir A., Corrêa-Nunes A., O'Connor D., Voordouw A., Westermark K., Sepodes B., 'Use of biomarkers in the context of orphan medicines designation in the European Union', Orphanet J Rare Dis, Vol. 9(1), 13.stylianos.tsigkos@ema.europa.eu
Tsigkos S., Mariz S., Llinares J., Fregonese L., Aarum S., Naumann-Winter F., Westermark K., Sepodes B., ‘Establishing medical plausibility in the context of orphan medicines designation in the European Union’, Orphanet Journal of Rare Diseases, Vol. 9: 175.stylianos.tsigkos@ema.europa.eu
The Expert Panel on Therapeutic Products for Infants, Children, and Youth, ‘Improving Medicines for Children in Canada’, the Council of Canadian Academies.-
van Aerts L. A., De Smet K., Reichmann G., Willem van der Laan J., Schneider C. K., 'Biosimilars entering the clinic without animal studies: A paradigm shift in the European Union', MAbs 6(5), pp. 1155-1162.la.v.aerts@cbg-meb.nl
van Riet-Nales D. A., Römkens E. G., Saint-Raymond A., Kozarewicz P., Schobben A. F., Egberts T. C., Rademaker C. M., 'Oral medicines for children in the European paediatric investigation plans', PLoS One., Vol. 9(6), p. e98348agnes.saint-raymond@ema.europa.eu
Vetter T., GFR Decline as an End Point for Clinical Trials in CKD: A View From Europe, Am J Kidney Dis, Vol. 64(6), pp. 838-840.thorsten.vetter@ema.europa.eu

 

2013

Back to top

PublicationCorresponding author
Baird L. G., Trusheim M. R., Eichler H. G., Berndt E. R., Hirsch G., 'Comparison of stakeholder metrics for traditional and adaptive development and licensing approaches to drug development', Therapeutic Innovation & Regulatory Science, Vol. 47(4), pp. 474-483.lbaird@mit.edu
Barkholt L., Flory E., Jekerle V., Lucas-Samuel S., Ahnert P., Bisset L., Büscher D., Fibbe W., Foussat A., Kwa M., Lantz O., Mačiulaitis R., Palomäki T., Schneider C. K., Sensebé L., Tachdjian G., Tarte K., Tosca L., Salmikangas P., 'Risk of tumorigenicity in mesenchymal stromal cell-based therapies - bridging scientific observations and regulatory viewpoints', Cytotherapy, Vol. 15(7), pp. 753-759.paula.salmikangas@fimea.fi
Berntgen M., Enzmann H., Schabel E., Prieto Yerro C., Gómez-Outes A., Salmonson T., Musaus J., 'Linaclotide for treatment of irritable bowel syndrome - the view of European regulators', Dig Liver Dis, Vol. 45(9), pp. 724–726.michael.berntgen@ema.europa.eu
Berrut G., Andrieu S., Araujo de Carvalho I., Baeyens J. P., Bergman H., Cassim B., Cerreta F., Cesari M., Cha H. B., Chen L. K., Cherubini A., Chou M. Y., Cruz-Jentoft A. J., De Decker L., Du P., Forette B., Forette F., Franco A., Guimaraes R., Guttierrez-Robledo L. M., Jauregui J., Khavinson V., Lee W. J., Peng L. N., Perret-Guillaume C., Petrovic M., Retornaz F., Rockwood K., Rodriguez-Manas L., Sieber C., Spatharakis G., Theou O., Topinkova E., Vellas B., Benetos A., 'Promoting access to innovation for frail old persons. IAGG (International Association of Gerontology and Geriatrics), WHO (World Health Organization) and SFGG (Société Française de Gériatrie et de Gérontologie) Workshop - Athens January 20-21, 2012 Tool (GFST)', J Nutr Health Aging, Vol. 17(8), pp. 688-693.a.benetos@chu-nancy.fr
Beyer A. R., Fasolo B., Phillips L. D., de Graeff P. A., Hillege H. L., 'Risk perception of prescription drugs: results of a survey among experts in the European regulatory network', Med Decis Making, Vol. 33(4), pp. 579-592.andrea.beyer@ema.europa.eu
Brassart, L., Skarlatos A., Papaluca M., Camanas Saez L., Cerreta F., 'Product information and older people: how to assist informed prescription and safe therapeutic use?', Regulatory Rapporteur, Vol. 10(7/8).-
Breckenridge A., Eichler H. G., 'Towards a prevention model of health care', Nat Rev Drug Discov, Vol. 2(8), pp. 563-564.ambreck@liv.ac.uk
hans-georg.eichler@ema.europa.eu
Butlen-Ducuing F., Guelfi J. D., 'Méthodes d’étude chez l'homme', in: Les antidépresseurs, Lavoisier, January 2013.florence.butlen@ema.europa.eu
Callréus T., Schneider C. K., 'The emergence of regulatory science in pharmaceutical medicine', Pharm Med, Vol. 27(6), pp. 345-351.tca@dkma.dk
da Rocha Dias S., Salmonson T., van Zwieten-Boot B., Jonsson B., Marchetti S., Schellens J. H., Giuliani R., Pignatti F., 'The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Eur J Cancer, Vol. 49(7), pp. 1654-1661.silvy.darochadias@ema.europa.eu
Egger G. F., Herold R., Rodriguez A., Manent N., Sweeney F., Saint-Raymond A., 'European Union Clinical Trials Register: on the way to more transparency of clinical trial data', Expert Rev Clin Pharmacol, Vol. 6(5), pp. 457-459.gunter.egger@ema.europa.eu
Ehmann F., Papaluca Amati M., Salmonson T., Posch M., Vamvakas S., Hemmings R., Eichler H. G., Schneider C. K., 'Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude', Clin Pharmacol Ther, Vol. 93(5), pp. 425–432.falk.ehmann@ema.europa.eu
Ehmann F., Sakai-Kato K., Duncan R., Hernán Pérez de la Ossa D., Pita R., Vidal J. M., Kohli A., Tothfalusi L., Sanh A., Tinton S., Robert J. L., Silva Lima B., Papaluca Amati M., 'Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines', Nanomedicine (Lond), Vol. 8(5), pp. 849-856.falk.ehmann@ema.europa.eu
Eichler H. G., Bloechl-Daum B., Brasseur D., Breckenridge A., Leufkens H., Raine J., Salmonson T., Schneider C. K., Rasi G., 'The risks of risk aversion in drug regulation', Nat Rev Drug Discov, Vol. 12(12), pp. 907-916.brigitte.bloechl-daum@meduniwien.ac.at
Eichler H. G., Pétavy F., Pignatti F., Rasi G. 'Access to patient-level trial data - a boon to drug developers', N Engl J Med, Vol. 369(17), pp. 1577-1579.-
Elmgren L., Li X., Wilson C., Ball R., Wang J., Cichutek K., Pfleiderer M., Kato A., Cavaleri M., Southern J., Jivapaisarnpong T., Minor P., Griffiths E., Sohn Y., Wood D., 'A global regulatory science agenda for vaccines', Vaccine, Vol. 31 Suppl 2, pp. B163-B175.woodd@who.int
Franco P., 'Orphan drugs: the regulatory environment', Drug Discov Today, Vol. 18(3-4), pp. 163-172.pedro.franco@ema.europa.eu
Gravanis I., 'Geriatric oncology: European Union regulatory perspectives and initiatives', J Geriatr Oncol, Vol. 4(2), pp. 202-204.iordanis.gravanis@ema.europa.eu
Gravanis I., Lopez A. S., Hemmings R. J., Jiménez J. C., Garcia-Carbonero R., Gallego I. G., Giménez E. V., O'Connor D., Giuliani R., Salmonson T., Pignatti F., 'The European Medicines Agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Oncologist, Vol. 18(9), pp. 1032-1042.iordanis.gravanis@ema.europa.eu
Henshall C., Sansom L., Eichler H.-G., Lemgruber A., Longson C., O’Rourke B., Tunis S., 'Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies. What are they looking for, and how and why does this differ from what regulators require?', Therapeutic Innovation & Regulatory Science, 28 November 2013.consulting@chrishenshall.co.uk
Hilger A., Arras-Reiter C., Keller-Stanislawski B., Ljungberg B., Male C., Mentzer D., Seitz R., Silvester G., 'Comment on: Mannucci, P. M. Evolution of the European guidelines for the clinical development of factor VIII products', Haemophilia, Vol. 19(3), pp. 349-350.glenda.silvester@ema.europa.eu
Janssens E., 'Pharmaceuticals: EU initiative to tackle medication errors – Proposals and challenges', Eur J Risk Regulation, Vol. 3/2013, pp. 388-391.-
Karres J., Tomasi P., 'New medicines for type 2 diabetes in adolescents: many products, few patients', Expert Rev Clin Pharmacol, Vol. 6(3), pp. 227-229.janina.karres@ema.europa.eu
Köhne C. H., Bedenne L., Carrato A., Bouché O., Popov I., Gaspà L., Valladares M., Rougier P., Gog C., Reichardt P., Wils J., Pignatti F., Biertz F., 'A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study', Eur J Cancer, Vol. 49(8), pp. 1868-1875.onkologie@klinikum-oldenburg.de
Liberti L., McAuslane N., Patel P., Breckenridge A., Eichler H. G., Peterson R., 'Regulatory review: How do agencies ensure the quality of decision making?', Clin Pharmacol Ther, Vol. 94(3), pp. 305-308.-
Lionetti G., Kimura Y., Schanberg L. E., Beukelman T., Wallace C. A., Ilowite N. T., Winsor J., Fox K., Natter M., Sundy J. S., Brodsky E., Curtis J. R., Del Gaizo V., Iyasu S., Jahreis A., Meeker-O'Connell A., Mittleman B. B., Murphy B. M., Peterson E. D., Raymond S. C., Setoguchi S., Siegel J. N., Sobel R. E., Solomon D., Southwood T. R., Vesely R., White P. H., Wulffraat N. M., Sandborg C. I., 'Using registries to identify adverse events in rheumatic diseases', Pediatrics, Vol. 132(5), e1384-e1394.ykimura@hackensackumc.org
Maignen F., Hauben M., Hung E., Holle L. V., Dogne J. M., 'A conceptual approach to the masking effect of measures of disproportionality', Pharmacoepidemiol Drug Saf, Vol. 23(2), pp. 208-217.francois.maignen@ema.europa.eu
Maignen F., Hauben M., Hung E., Van Holle L., Dogne J. M., 'Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases', Pharmacoepidemiol Drug Saf, Vol. 23(2), pp. 195-207.francois.maignen@ema.europa.eu
Maliepaard M., Nofziger C., Papaluca M., Zineh I., Uyama Y., Prasad K., Grimstein C., Pacanowski M., Ehmann F., Dossena S., Paulmichl M., 'Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective', Nat Rev Drug Discov, Vol. 12(2), pp. 103-115.markus.paulmichl@pmu.ac.at
Manolis E., Rohou S., Hemmings R., Salmonson T., Karlsson M., Milligan P. A.. 'The role of modeling and simulation in development and registration of medicinal products: Output from the EFPIA / EMA Modeling and Simulation Workshop', CPT Pharmacometrics Syst Pharmacol, Vol. 2, e31.efthymios.manolis@ema.europa.eu
Marshall S. F., Hemmings R., Josephson F., Karlsson M. O., Posch M., Steimer J. L., 'Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims', CPT Pharmacometrics Syst Pharmacol, Vol. 2, e27.scott.marshall@pfizer.com
Melchiorri D., Pani L., Gasparini P., Cossu G., Ancans J., Borg J. J., Drai C., Fiedor P., Flory E., Hudson I., Leufkens H. G., Müller-Berghaus J., Narayanan G., Neugebauer B., Pokrotnieks J., Robert J. L., Salmonson T., Schneider C. K., 'Regulatory evaluation of Glybera in Europe - two committees, one mission', Nat Rev Drug Discov, Vol. 12(9), p. 719.chsc@dkma.dk
Péan E., Flores B., Hudson I., Sjöberg J., Dunder K., Salmonson T., Gisselbrecht C., Laane E., Pignatti F., 'The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Oncologist, Vol. 18(5), pp. 625-633.elias.pean@ema.europa.eu
Phillips L. D., Fasolo B., Zafiropoulous N., Eichler H. G., Ehmann F., Jekerle V., Kramarz P., Nicoll A., Lönngren T., 'Modelling the risk-benefit impact of H1N1 influenza vaccines', Eur J Public Health, Vol. 23(4), pp. 674-678.larry_phillips@msn.com
Putzeist M., Mantel-Teeuwisse A. K., Llinares J., Gispen-De Wied C. C., Hoes A. W., Leufkens H. G., 'EU marketing authorization review of orphan and non-orphan drugs does not differ', Drug Discov Today, Vol. 18(19–20), pp. 1001–1006.m.putzeist@uu.nl
Ruperto N., Vesely R., Saint-Raymond A., Martini A., 'Impact of the European paediatric legislation in paediatric rheumatology: past, present and future', Ann Rheum Dis, Vol. 72(12), pp.1893-1896.nicolaruperto@ospedale-gaslini.ge.it
Schneider C. K., 'The ethics of biosimilars', GaBI J, Vol. 2(1), pp. 6-7.-
Slattery J., Alvarez Y., Hidalgo A., 'Choosing thresholds for statistical signal detection with the proportional reporting ratio', Drug Saf, Vol. 36(8), pp. 687-692.jim.slattery@ema.europa.eu
Staab A., Rook E., Maliepaard M., Aarons L., Benson C., 'Modeling and simulation in clinical pharmacology and dose finding', CPT Pharmacometrics Syst Pharmacol, Vol. 2, e29.alexander.staab@boehringer-ingelheim.com
Stephenson D., Aviles E., Bain L. J., Brumfield M., Carrillo M., Comery T. A., Compton C., Corrigan B., Forrest Gordon M., Jack C. R., Katz R., Logovinsky V., Satlin A., Marek K., Nicholas T., Polhamus D., Angersbach B. S., Raghavan N., Romano G., Romero K., Shaw L., Woodcock J., Vradenburg G., Isaac M., 'Coalition Against Major Diseases:
precompetitive collaborations and regulatory paths to accelerating drug development for neurodegenerative diseases
', Therapeutic Innovation & Regulatory Science, Vol. 47(6), pp. 632-638.
dstephenson@c-path.org
Tomasi P., 'Paediatric clinical trials: need for capacity building', J Clin Stud, Vol. 5(3), pp. 10-16.paolo.tomasi@ema.europa.eu
Tomasi P., Saint-Raymond A., 'Scope of the PIP in the EU: easier accessibility to the paediatric rewards and simplification of administrative requirements', Scrip Regulatory Affairs, January 2013, p. 5.-
Tzogani K., Straube M., Hoppe U., Kiely P., O'Dea G., Enzmann H., Salmon P., Salmonson T., Pignatti F., 'The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use', J Dermatolog Treat, Vol. 25(5), pp. 371-374.kyriaki.tzogani@ema.europa.eu
van Riet Nales D. A., Kozarewicz P., Wang S., Saint-Raymond A., Robert J. L., 'Comments on the EMA draft guideline: final steps towards a harmonized view between regulators and industry', Int J Pharm, Vol. 457(1), pp. 337-339.da.v.riet@cbg-meb.nl
Vaquer G., Rivière F., Mavris M., Bignami F., Llinares-Garcia J., Westermark K., Sepodes B., 'Animal models for metabolic, neuromuscular and ophthalmological rare diseases', Nat Rev Drug Discov, Vol. 12(4), pp. 287-305.bsepodes@ff.ul.pt
Vermeer N. S., Straus S. M., Mantel-Teeuwisse A. K., Domergue F., Egberts T. C., Leufkens H. G., De Bruin M. L., 'Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases', Drug Saf, Vol. 36(8), pp. 617-625.m.l.debruin@uu.nl
Vestergaard H. T., D'Apote L., Schneider C. K., Herberts C., 'The evolution of nonclinical regulatory science: advanced therapy medicinal products as a paradigm', Mol Ther, Vol. 21(9), pp. 1644-1648.-
Vidal J. M., 'Non-clinical science and regulatory approach. An introduction', Toxicologische Communicatie, Data en Documentatie, Vol. 3, pp. 14-15.-
Visser S. A., Manolis E., Danhof M., Kerbusch T., 'Modeling and simulation at the interface of nonclinical and early clinical drug development', CPT Pharmacometrics Syst Pharmacol, Vol. 2, e30.sandra.visser@merck.com

 

2012

Back to top

PublicationCorresponding author
Bahri P., Harrison-Woolrych M., 'Focusing on risk communication about medicines: why now?', Drug Saf, Vol. 35(11), pp. 971-975.priya.bahri@ema.europa.eu
Bahri P., Harrison-Woolrych M., 'How to improve communication for the safe use of medicines? Discussions on social marketing and patient-tailored approaches at the annual meetings of the WHO Programme for International Drug Monitoring', Drug Saf, Vol. 35(12), pp. 1073-1079.priya.bahri@ema.europa.eu
Blake K. V., Devries C. S., Arlett P., Kurz X., Fitt H., 'Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance', Pharmacoepidemiol Drug Saf, Vol. 21(7), pp. 690-696.kevin.blake@ema.europa.eu
Butlen-Ducuing F., Haas M., Pani L., van Zwieten-Boot B., Broich K., 'DSM-5 and clinical trials in psychiatry: challenges to come?', Nat Rev Drug Discov, Vol. 11(8), pp. 583-584.florence.butlen@ema.europa.eu
Calderon M. A., Gerth van Wijk R., Eichler I., Matricardi P. M., Varga E. M., Kopp M. V., Eng P., Niggemann B., Nieto A., Valovirta E., Eigenmann P. A., Pajno G., Bufe A., Halken S., Beyer K., Wahn U., European Academy of Allergy and Clinical Immunology, 'Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement', Pediatr Allergy Immunol, Vol. 23(4), pp. 300-306.m.calderon@imperial.ac.uk
Cerreta F., Eichler H. G., Rasi G., 'Drug policy for an aging population — the European Medicines Agency's geriatric medicines strategy', N Engl J Med, Vol. 367(21), pp. 1972-1974.francesca.cerreta@ema.europa.eu
Cesari M., Fielding R. A., Pahor M., Goodpaster B., Hellerstein M., van Kan G. A., Anker S. D., Rutkove S., Vrijbloed J. W., Isaac M., Rolland Y., M'rini C., Aubertin-Leheudre M., Cedarbaum J. M., Zamboni M., Sieber C. C., Laurent D., Evans W. J., Roubenoff R., Morley J. E., Vellas B., International Working Group on Sarcopenia, 'Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia', J Cachexia Sarcopenia Muscle, Vol. 3(3), pp. 181-190.macesari@gmail.com
roger.fielding@tufts.edu
Eichler H. G., Abadie E., Baker M., Rasi G., 'Fifty years after thalidomide; what role for drug regulators?', Br J Clin Pharmacol, Vol. 74(5), pp. 731-733.hans-georg.eichler@ema.europa.eu
Eichler H. G., Abadie E., Breckenridge A., Leufkens H., Rasi G., 'Open clinical trial data for all? A view from regulators', PLoS Med, Vol. 9(4), e1001202.hans-georg.eichler@ema.europa.eu
Eichler H. G., Oye K., Baird L. G., Abadie E., Brown J., Drum C. L., Ferguson J., Garner S., Honig P., Hukkelhoven M., Lim J. C., Lim R., Lumpkin M. M., Neil G., O'Rourke B., Pezalla E., Shoda D., Seyfert-Margolis V., Sigal E. V., Sobotka J., Tan D., Unger T. F., Hirsch G., 'Adaptive licensing: taking the next step in the evolution of drug approval', Clin Pharmacol Ther, Vol. 91(3), pp. 426-437.oye@mit.edu
Gaydos B., Koch A., Miller F., Posch M., Vandemeulebroecke M., Wang S.-J., 'Perspective on adaptive designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance – where are we now?', Clin Invest, Vol. 2(3), pp. 235-240.marc.vandemeulebroecke@novartis.com
Gispen-de Wied C., Stoyanova V., Yu Y., Isaac M., Pani L., de Andres-Trelles F., 'The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma', Eur Neuropsychopharmacol, Vol. 22(11), pp. 804-811.cc.gispen@cbg-meb.nl
Grave K., Greko C., Kvaale M. K., Torren-Edo J., Mackay D., Muller A., Moulin G., ESVAC Group, 'Sales of veterinary antibacterial agents in nine European countries during 2005-09: trends and patterns', J Antimicrob Chemother, Vol. 67(12), pp. 3001-3008.kari.grave@ema.europa.eu
Grein K., 'Responsibilities of regulatory agencies in the marketing of antimicrobials', Rev Sci Tech, Vol. 31(1), pp. 289-298.-
Hidalgo-Simon A., Arlett P., 'Pharmacovigilance in Europe: direction of travel in a changing environment', Expert Rev Clin Pharmacol, Vol. 5(5), pp. 485-488.ana.hidalgo-simon@ema.europa.eu
Isaac M., Pani L., Gispen-de Wied C., Koch A., 'European licensing of maintenance treatment in schizophrenia', Lancet, Vol. 380(9841), pp. 562-563.maria.isaac@ema.europa.eu
Isai A., Durand J., Le Meur S., Hidalgo-Simon A., Kurz X., 'Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review', Vaccine, Vol. 30(49), pp. 7123-7129.julie.durand@ema.europa.eu
Klug B., Celis P., Carr M., Reinhardt J., 'Regulatory structures for gene therapy medicinal products in the European Union', In: Freeman T. (ed.), Gene transfer vectors for clinical application, United Kingdom, Academic Press, pp. 337-354.-
Lumpkin M. M., Eichler H. G., Breckenridge A., Hamburg M. A., Lönngren T., Woods K., 'Advancing the science of medicines regulation: the role of the 21st-century medicines regulator', Clin Pharmacol Ther, Vol. 92(4), pp. 486-493.murray.lumpkin@fda.hhs.gov
Maciulaitis R., D'Apote L., Buchanan A., Pioppo L., Schneider C. K., 'Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive', Mol Ther, 20(3), pp. 479-482.chsc@dkma.dk
Maxwell S., Eichler H. G., Bucsics A., Haefeli W. E., Gustafsson L. L., e-SPC Consortium, 'e-SPC - delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers', Br J Clin Pharmacol, Vol. 73(1), pp. 12-15.s.maxwell@ed.ac.uk
Mischak H., Ioannidis J. P., Argiles A., Attwood T. K., Bongcam-Rudloff E., Broenstrup M., Charonis A., Chrousos G. P., Delles C., Dominiczak A., Dylag T., Ehrich J., Egido J., Findeisen P., Jankowski J., Johnson R. W., Julien B. A., Lankisch T., Leung H. Y., Maahs D., Magni F., Manns M. P., Manolis E., Mayer G., Navis G., Novak J., Ortiz A., Persson F., Peter K., Riese H. H., Rossing P., Sattar N., Spasovski G., Thongboonkerd V., Vanholder R., Schanstra J. P., Vlahou A., 'Implementation of proteomic biomarkers: making it work', Eur J Clin Invest, Vol. 42(9), pp. 1027-1036.harald.mischak@glasgow.ac.uk
Mullier F., Rahier J. F., Maignen F., Cornet Y., Graux C., Chatelain C., Chatelain B., Dogne J. M., 'A case of therapy-related myeloid neoplasm in a patient with Crohn's disease treated with azathioprine', Acta Haematol, Vol. 128(1), pp. 1-6.mullierfrancois@gmail.com
Pean E., Demolis P., Moreau A., Hemmings R. J., O'Connor D., Brown D., Shepard T., Abadie E., Pignatti F., 'The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Oncologist, Vol. 17(4), pp. 543-549.elias.pean@ema.europa.eu
Pean E., Klaar S., Berglund E. G., Salmonson T., Borregaard J., Hofland K. F., Ersbøll J., Abadie E., Giuliani R., Pignatti F., 'The European Medicines Agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Clin Cancer Res, Vol. 18(17), pp. 4491-4497.elias.pean@ema.europa.eu
Pelkonen O., Abass K., Wiesner J., 'Thujone and thujone-containing herbal medicinal and botanical products: toxicological assessment', Regul Toxicol Pharmacol, Vol. 65(1), pp. 100-107.olavi.pelkonen@oulu.fi
Pignatti F., Flores B., Jonsson B., 'Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective', Am J Hematol, Vol. 87, pp. 943-944.francesco.pignatti@ema.europa.eu
Posch M., Proschan M. A., 'Unplanned adaptations before breaking the blind', Stat Med, Vol. 31(30), pp. 4146-4153.martin.posch@ema.europa.eu
Prieto L., Spooner A., Hidalgo-Simon A., Rubino A., Kurz X., Arlett P., 'Evaluation of the effectiveness of risk minimization measures', Pharmacoepidemiol Drug Saf, Vol. 21(8), pp. 896-899.luis.prieto@ema.europa.eu
Putzeist M., Mantel-Teeuwisse A. K., Aronsson B., Rowland M., Gispen-de Wied C. C., Vamvakas S., Hoes A. W., Leufkens H. G., Eichler H. G., 'Factors influencing non-approval of new drugs in Europe', Nat Rev Drug Discov, Vol. 11(12), pp. 903-904.-
Quigley K., 'Veterinary medicines: What is the MUMS / limited markets policy?', Regulatory Rapporteur, Vol. 10(2).-
Saint-Raymond A., Herold R., 'Medicines for pediatric oncology: can we overcome the failure to deliver?', Expert Rev Clin Pharmacol, Vol. 5(5), pp. 493-495.agnes.saint-raymond@ema.europa.eu
Sala Soriano E., Eichler I., Helms P. J., 'Joined-up thinking', European Pharmaceutical Contractor, March 2012, pp. 35-36.-
Schneider C. K., Vleminckx C., Gravanis I., Ehmann F., Trouvin J. H., Weise M., Thirstrup S., 'Setting the stage for biosimilar monoclonal antibodies', Nat Biotechnol, Vol. 30(12), pp. 1179-1185.c_schneid@web.de
Stegemann S., Baeyens J.-P., Cerreta F., Chanied E., Löfgren A., Maio M., Schreier G., Thesing-Bleck E., 'Adherence measurement systems and technology for medications in older patient populations', Eur Geriatr Med, Vol. 3(4), pp. 254-260.sven.stegemann@capsugel.com
Tomasi P., 'Writing applications for paediatric investigation plans and waivers', Medical Writing, Vol. 21(2), pp. 104-107.paolo.tomasi@ema.europa.eu
van Riet-Nales D. A., Wang S., Saint-Raymond A., Robert J. L., 'The EMA quality guideline on the pharmaceutical development of medicines for paediatric use', Int J Pharm, Vol. 435(2), pp. 132-134.da.v.riet@cbg-meb.nl
Veselý R., Haf Davies E., 'Helping the medicine go down', Public Service Review: European Science & Technology, Vol. 14, pp. 1-2.-
Videnova K., Mackay D. K., 'Availability of vaccines against major animal diseases in the European Union', Rev Sci Tech, Vol. 31(3), pp. 971-978.-
Vinhas de Souza M., Keller-Stanislawski B., Blake K., Hidalgo-Simon A., Arlett P., Dal Pan G., 'Drug-induced PML: a global agenda for a global challenge', Clin Pharmacol Ther, Vol. 91(4), pp. 747-750.ana.hidalgo-simon@ema.europa.eu
Westermark K., Llinares J., 'Promoting the development of drugs against rare diseases: what more should be done?', Expert Rev Pharmacoecon Outcomes Res, Vol. 12(5), pp. 541-543.jordi.llinares@ema.europa.eu
Zafiropoulos N., Phillips L., Pignatti F., Luria X., 'Evaluating benefit–risk: an Agency perspective', Regulatory Rapporteur, Vol. 9(6), pp. 5-8.-
Zehetmayer S., Posch M., 'False discovery rate control in two-stage designs', BMC Bioinformatics, Vol. 13, 81.sonja.zehetmayer@meduniwien.ac.at
Zomerdijk I. M., Sayed-Tabatabaei F. A., Trifirò G., Blackburn S. C., Sturkenboom M. C., Straus S. M., 'Risk minimization activities of centrally authorized products in the EU: a descriptive study', Drug Saf, Vol. 35(4), pp. 299-314.i.zomerdijk@erasmusmc.nl

 

2011

Back to top

PublicationCorresponding author
Arlett P.R., Kurz X., 'New approaches to strengthen pharmacovigilance', Drug Discov Today Technol, Vol. 8(1), e15–e19.xavier.kurz@ema.europa.eu
Arnardottir A. H., Haaijer-Ruskamp F. M., Straus S. M., Eichler H. G., de Graeff P. A., Mol P. G., 'Additional safety risk to exceptionally approved drugs in Europe?', Br J Clin Pharmacol, Vol. 72(3), pp. 490-499.a.h.arnardottir@med.umcg.nl
Bahri P., Mol P. G., Théophile H., Edwards I. R., Hugman B. P., 'Communication in drug safety: a report from an interactive debate held at the 10th annual meeting of the International Society of Pharmacovigilance (ISoP), 2010', Drug Saf, Vol. 34(10), pp. 881-882.priya.bahri@ema.europa.eu
Blake K. V., Prilla S., Accadebled S., Guimier M., Biscaro M., Persson I., Arlett P., Blackburn S., Fitt H., 'European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance', Pharmacoepidemiol Drug Saf, Vol. 20(10), pp. 1021-1029.kevin.blake@ema.europa.eu
Blake K. V., Smeraldi C., Kurz X., Arlett P., Blackburn S., Fitt H., 'The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance: application to diabetes and vascular disease', British Journal of Diabetes & Vascular Disease, Vol. 11(6), pp. 304-307.kevin.blake@ema.europa.eu
Büttel I. C., Chamberlain P., Chowers Y., Ehmann F., Greinacher A., Jefferis R., Kramer D., Kropshofer H., Lloyd P., Lubiniecki A., Krause R., Mire-Sluis A., Platts-Mills T., Ragheb J. A., Reipert B. M., Schellekens H., Seitz R., Stas P., Subramanyam M., Thorpe R., Trouvin J. H., Weise M., Windisch J., Schneider C. K., 'Taking immunogenicity assessment of therapeutic proteins to the next level', Biologicals, Vol. 39(2), pp. 100-109.bueis@pei.de
Carleer J., Karres J., 'Juvenile animal studies and pediatric drug development: a European regulatory perspective', Birth Defects Res B Dev Reprod Toxicol, Vol. 92(4), pp. 254-260.jacqueline.carleer@afmps.be
De Mattia F., Chapsal J. M., Descamps J., Halder M., Jarrett N., Kross I., Mortiaux F., Ponsar C., Redhead K., McKelvie J., Hendriksen C., 'The consistency approach for quality control of vaccines - a strategy to improve quality control and implement 3Rs', Biologicals, Vol. 39(1), pp. 59-65.fabrizio.de.mattia@spcorp.com
Ehmann F., Schneider C. K., 'Biosimilar monoclonal antibodies: The implications', Hospital Pharmacy Europe, Vol. 56, May/June 2011.falk.ehmann@ema.europa.eu
Eichler H. G., Abadie E., Breckenridge A., Flamion B., Gustafsson L. L., Leufkens H., Rowland M., Schneider C. K., Bloechl-Daum B., 'Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response', Nat Rev Drug Discov, Vol. 10(7), pp. 495-506.brigitte.bloechl-daum@meduniwien.ac.at
Eichler I., Soriano E. S., 'Close collaboration between academia, industry and drug regulators is required in the development of allergen products for specific immunotherapy in children', Allergy, Vol. 66(8), pp. 999-1004.irmgard.eichler@ema.europa.eu
Freire-Moran L., Aronsson B., Manz C., Gyssens I. C., So A. D., Monnet D. L., Cars O., ECDC-EMA Working Group, 'Critical shortage of new antibiotics in development against multidrug-resistant bacteria - time to react is now', Drug Resist Updat, Vol. 14(2), pp. 118-124.otto.cars@medsci.uu.se
Hanaizi Z., van Zwieten-Boot B., Calvo G., Lopez A. S., van Dartel M., Camarero J., Abadie E., Pignatti F., 'The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Eur J Cancer, Vol. 48, pp. 237-242.zahra.hanaizi@ema.europa.eu
Hatzakis A., Wait S., Bruix J., Buti M., Carballo M., Cavaleri M., Colombo M., Delarocque-Astagneau E., Dusheiko G., Esmat G., Esteban R., Goldberg D., Gore C., Lok A. S., Manns M., Marcellin P., Papatheodoridis G., Peterle A., Prati D., Piorkowsky N., Rizzetto M., Roudot-Thoraval F., Soriano V., Thomas H. C., Thursz M., Valla D., van Damme P., Veldhuijzen I. K., Wedemeyer H., Wiessing L., Zanetti A. R., Janssen H. L., 'The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference', J Viral Hepat, Vol. 18 Suppl 1, pp. 1-16.ahatzak@med.uoa.gr
Heininger U., Bachtiar N. S., Bahri P., Dana A., Dodoo A., Gidudu J., Santos E. M., 'The concept of vaccination failure', Vaccine, Vol. 30(7), pp. 1265-1268.ulrich.heininger@ukbb.ch
Isaac M., Vamvakas S., Abadie E., Jonsson B., Gispen C., Pani L., 'Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden - regulatory considerations by European Medicines Agency focusing in improving benefit', Eur Neuropsychopharmacol, Vol. 21(11), pp. 781-788.maria.isaac@ema.europa.eu
Karres J., Tomasi P., Saint-Raymond A., 'The development of pharmacological treatment of obesity in children. A European regulatory perspective', Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, Vol. 54(5), pp. 570-576.janina.karres@ema.europa.eu
Korakianiti E., Rekkas D., 'Statistical thinking and knowledge management for quality-driven design and manufacturing in pharmaceuticals', Pharm Res, Vol. 28(7), pp. 1465-1479.rekkas@pharm.uoa.gr
Kurz X., Domergue F., Slattery J., Segec A., Szmigiel A., Hidalgo-Simon A., 'Safety monitoring of influenza A/H1N1 pandemic vaccines in EudraVigilance', Vaccine, Vol. 29(26), pp. 4378-4387.xavier.kurz@ema.europa.eu
Leufkens H. G., Eichler H. G., 'Innovative methods in drug regulatory sciences', Drug Discov Today Technol, Vol. 8(1), e1-e2.h.g.m.leufkens@uu.nl
Leufkens H. G., Schellekens H., Aronsson B., 'Post-innovation innovation of medicinal products', Drug Discov Today Technol, Vol. 8(1), e37-e41.h.g.m.leufkens@uu.nl
Manolis E., Herold R., 'Pharmacometrics for regulatory decision making: status and perspective', Clin Pharmacokinet, Vol. 50(10), pp. 625-626.ralf.herold@ema.europa.eu
Manolis E., Osman T. E., Herold R., Koenig F., Tomasi P., Vamvakas S., Saint-Raymond A., 'Role of modeling and simulation in pediatric investigation plans', Paediatr Anaesth, Vol. 21(3), pp. 214-221.efthymios.manolis@ema.europa.eu
Manolis E., Vamvakas S., Isaac M., 'New pathway for qualification of novel methodologies in the European Medicines Agency', Proteomics Clin Appl, Vol. 5(5-6), pp. 248-255.efthymios.manolis@ema.europa.eu
Mariz S., Llinares J., Westermark K., 'Orphan drugs. EU regulations', BMJ, Vol. 342, d136.segundo.mariz@ema.europa.eu
Matt P., van Zwieten-Boot B., Calvo Rojas G., Ter Hofstede H., Garcia-Carbonero R., Camarero J., Abadie E., Pignatti F, 'The European Medicines Agency review of tegafur / gimeracil / oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Oncologist, Vol. 16(10), pp. 1451-1457.petra.matt@ema.europa.eu
Müllner M., Eichler H.-G., 'Current issues in drug regulation', In: M. Müllner (ed.), Clinical Pharmacology: Current Topics and Case Studies, Springer Vienna, pp. 19-31.-
Nieto M., Borregaard J., Ersbøll J., ten Bosch G. J., van Zwieten-Boot B., Abadie E., Schellens J. H., Pignatti F., 'The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Clin Cancer Res, Vol. 17(21), pp. 6608-6614.maria.nietogutierrez@ema.europa.eu
Nieto M., Calvo G., Hudson I., Feldschreiber P., Brown D., Lee C. C., Lay G., Valeri A., Abadie E., Thomas A., Pignatti F., 'The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use', Haematologica, Vol. 96(9), e33-e40.maria.nietogutierrez@ema.europa.eu
Olski T. M., Lampus S. F., Gherarducci G., Saint Raymond A., 'Three years of paediatric regulation in the European Union', Eur J Clin Pharmacol, Vol. 67(3), pp. 245-252.agnes.saint-raymond@ema.europa.eu
Phillips L. D., Fasolo B., Zafiropoulos N., Beyer A., 'Is quantitative benefit-risk modelling of drugs desirable or possible?' Drug Discov Today Technol, Vol. 8(1), e3–e10.lawrence.phillips@ema.europa.eu
Pignatti F., Gravanis I., Herold R., Vamvakas S., Jonsson B., Marty M., 'The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation', Clin Cancer Res, Vol. 17(16), pp. 5220-5225.francesco.pignatti@ema.europa.eu
Pignatti F., Hemmings R., Jonsson B., 'Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?', Eur J Cancer, Vol. 47(12), pp. 1759-1762.francesco.pignatti@ema.europa.eu
Pignatti F., Luria X., Abadie E., Eichler H. G., 'Regulators, payers, and prescribers: can we fill the gaps?', Lancet Oncol, Vol. 12(10), pp. 930-931.francesco.pignatti@ema.europa.eu
Pirmohamed M., Friedmann P. S., Molokhia M., Loke Y. K., Smith C., Phillips E., La Grenade L., Carleton B., Papaluca-Amati M., Demoly P., Shear N. H., 'Phenotype standardization for immune-mediated drug-induced skin injury', Clin Pharmacol Ther, Vol. 89(6), pp. 896-901.munirp@liv.ac.uk
Putzeist M., Heemstra H. E., Llinares Garcia J., Mantel-Teeuwisse A. K., Gispen-De Wied C. C., Hoes A. W., Leufkens H. G., 'Determinants for successful marketing authorisation of orphan medicinal products in the EU', Drug Discov Today, Vol. 17(7-8), pp. 352-358.a.k.mantel@uu.nl
Rahmner P. B., Eiermann B., Korkmaz S., Gustafsson L. L., Gruvén M., Maxwell S., Eichler H. G., Vég A., 'Physicians’ reported needs of drug information at point of care in Sweden', Br J Clin Pharmacol, Vol. 73(1), pp. 115-125.pia.bastholm-rahmner@sll.se
Raine J., Wise L., Blackburn S., Eichler H. G., Breckenridge A., 'European perspective on risk management and drug safety', Clin Pharmacol Ther, Vol. 89(5), pp. 650-654.alasdair.breckenridge@mhra.gsi.gov.uk
Rocchi F., Tomasi P., 'The development of medicines for children', Pharmacol Res, Vol. 64(3), pp. 169-175.paolo.tomasi@ema.europa.eu
Ruperto N., Eichler I., Herold R., Vassal G., Giaquinto C., Hjorth L., Valls-i-Soler A., Peters C., Helms P. J., Saint Raymond A., 'A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)', Arch Dis Child, Vol. 97(3), pp. 185-188.nicolaruperto@ospedale-gaslini.ge.it
Salmikangas P., Celis P., 'Current challenges in the development of novel cell-based medicinal products', Regulatory Rapporteur, Vol. 8(7-8), pp. 4-7.-
Silva Lima B., 'EMA responds to criticism of reflection paper on non-clinical studies for generic nano-particle iron medicinal product applications', Scrip Regulatory Affairs, 12 August 2011.-
Vamvakas S., Martinalbo J., Pita R., Isaac M., 'On the edge of new technologies (advanced therapies, nanomedicines)', Drug Discov Today Technol, Vol. 8(1), e21-e28.spiros.vamvakas@ema.europa.eu
Vleminckx C., Ehmann F., 'Guidelines EMA pour le développement de médicaments biosimilaires', Oncologie, Vol. 13(5), pp. 191-195.camille.vleminckx@ema.europa.eu
Voltz-Girolt C., Celis P., Boucaumont M., D'Apote L., Pinheiro M. H., Papaluca-Amati M., 'The advanced therapy classification procedure. Overview of experience gained so far', Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, Vol. 54(7), pp. 811-815.caroline.voltz@ema.europa.eu
Weise M., Bielsky M. C., De Smet K., Ehmann F., Ekman N., Narayanan G., Heim H. K., Heinonen E., Ho K., Thorpe R., Vleminckx C., Wadhwa M., Schneider C. K., 'Biosimilars - Why terminology matters', Nat Biotechnol, Vol. 29(8), pp. 690-693.martina.weise@bfarm.de
Westermark K., Holm B. B., Söderholm M., Llinares-Garcia J., Rivière F., Aarum S., Butlen-Ducuing F., Tsigkos S., Wilk-Kachlicka A., N'Diamoi C., Borvendég J., Lyons D., Sepodes B., Bloechl-Daum B., Lhoir A., Todorova M., Kkolos I., Kubáčková K., Bosch-Traberg H., Tillmann V., Saano V., Héron E., Elbers R., Siouti M., Eggenhofer J., Salmon P., Clementi M., Krieviņš D., Matulevičiene A., Metz H., Vincenti A. C., Voordouw A., Dembowska-Bagińska B., Nunes A. C., Saleh F. M., Foltánová T., Možina M., Torrent i Farnell J., Beerman B., Mariz S., Evers M. P., Greene L., Thorsteinsson S., Gramstad L., Mavris M., Bignami F., Lorence A., Belorgey C., 'European regulation on orphan medicinal products: 10 years of experience and future perspectives', Nat Rev Drug Discov, Vol. 10(5), pp. 341-349.kerstin.westermark@mpa.se

Wirth S., Kelly D., Sokal E., Socha P., Mieli-Vergani G., Dhawan A., Lacaille F., Saint-Raymond A., Olivier S., Taminiau J., 'Guidance for clinical trials for children and adolescents with chronic hepatitis C', J Pediatr Gastroenterol Nutr, Vol. 52(2), pp. 233-237.

stefan.wirth@helios-kliniken.de

 

2010

Back to top

PublicationCorresponding author
Alvarez Y., Hidalgo A., Maignen F., Slattery J., 'Validation of statistical signal detection procedures in EudraVigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling', Drug Saf, Vol. 33(6), pp. 475-487.jim.slattery@ema.europa.eu
Bahri P., 'Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies', Drug Saf, Vol. 33(12), pp. 1065-1079.priya.bahri@ema.europa.eu
Bauer P., Koenig F., Brannath W., Posch M., 'Selection and bias - two hostile brothers', Stat Med, Vol. 29(1), pp. 1-13.franz.koenig@ema.europa.eu
Blind E., Dunder K., de Graeff P. A., Abadie E., 'Rosiglitazone: a European regulatory perspective', Diabetologia, Vol. 54(2), pp. 213-218.eberhard.blind@ema.europa.eu
Bloechl-Daum B., Butlen-Ducuing F., Llinares-Garcia J., 'Special situations, market fragmentation: orphan drugs for rare diseases' in: Clinical pharmacology: current topics and case studies, Vienna, New York, Springer.brigitte.bloechl-daum@meduniwien.ac.at
Brosch S., Spina A., 'Pharmaceuticals: International Conference on Harmonisation and Standardisation initiatives in the pharmaceutical domain', Eur J Risk Regulation, Vol. 3, pp. 274-276.-
Butlen-Ducuing F., Rivière F., Aarum S., Llinares-Garcia J., 'European Medicines Agency support mechanisms fostering orphan drug development', Drug News Perspect, Vol. 23(1), pp. 71-81.florence.butlen@ema.europa.eu
Butlen-Ducuing F., Tsigkos S. 'Ten years of orphan drug designation in Europe', EHJP Practice, Vol. 16(4), pp. 19-20.stylianos.tsigkos@ema.europa.eu
Davies E. H., Ollivier C. M., Saint-Raymond A., 'Paediatric investigation plans for pain: painfully slow!', Eur J Clin Pharmacol, Vol. 66(11), pp. 1091-1097.ollivierces@googlemail.com
Del Seppia I., 'Lost in translation': scientific names of medicine in a globalized world', Eur J Risk Regulation, Vol. 4, pp. 431-435.-
Dieterle F., Sistare F., Goodsaid F., Papaluca M., Ozer J. S., Webb C. P., Baer W., Senagore A., Schipper M. J., Vonderscher J., Sultana S., Gerhold D. L., Phillips J. A., Maurer G., Carl K., Laurie D., Harpur E., Sonee M., Ennulat D., Holder D., Andrews-Cleavenger D., Gu Y. Z., Thompson K. L., Goering P. L., Vidal J. M., Abadie E., Maciulaitis R., Jacobson-Kram D., Defelice A. F., Hausner E. A., Blank M., Thompson A., Harlow P., Throckmorton D., Xiao S., Xu N., Taylor W., Vamvakas S., Flamion B., Lima B. S., Kasper P., Pasanen M., Prasad K., Troth S., Bounous D., Robinson-Gravatt D., Betton G., Davis M. A., Akunda J., McDuffie J. E., Suter L., Obert L., Guffroy M., Pinches M., Jayadev S., Blomme E. A., Beushausen S. A., Barlow V. G., Collins N., Waring J., Honor D., Snook S., Lee J., Rossi P., Walker E., Mattes W., 'Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium', Nat Biotechnol, Vol. 28(5), pp. 455–462.frank.dieterle@novartis.com
Eichler H. G., Aronsson B., Abadie E., Salmonson T., 'New drug approval success rate in Europe in 2009', Nat Rev Drug Discov, Vol. 9(5), pp. 355-356.hans-georg.eichler@ema.europa.eu
Eichler H. G., Bloechl-Daum B., Abadie E., Barnett D., König F., Pearson S., 'Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers', Nat Rev Drug Discov, Vol. 9(4), pp. 277-291.brigitte.bloechl-daum@meduniwien.ac.at
Eichler H. G., Hemmings R. J., Vamvakas S., 'Where statisticians can contribute to address future challenges for drug regulatory agencies: a view from the European Medicines Agency (EMEA)', Stat Biopharm Res, Vol. 2(3), pp. 355-358.-
Goodsaid F. M., Amur S., Aubrecht J., Burczynski M. E., Carl K., Catalano J., Charlab R., Close S., Cornu-Artis C., Essioux L., Fornace A. J. Jr, Hinman L., Hong H., Hunt I., Jacobson-Kram D., Jawaid A., Laurie D., Lesko L., Li H. H., Lindpaintner K., Mayne J., Morrow P., Papaluca-Amati M., Robison T. W., Roth J., Schuppe-Koistinen I., Shi L., Spleiss O., Tong W., Truter S. L., Vonderscher J., Westelinck A., Zhang L., Zineh I., 'Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact', Nat Rev Drug Discov, Vol. 9(6), pp. 435-445.federico.goodsaid@fda.hhs.gov
Gravanis I., Ersbøll J., Skovlund E., Abadie E., Marty M., Pignatti F., 'The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European Medicines Agency Committee for Medicinal Products for Human Use', Oncologist, Vol. 15(12), pp. 1335-1343.iordanis.gravanis@ema.europa.eu
Grave K., Torren Edo J., Mackay D., 'Comparison of the sales of veterinary antibacterial agents between 10 European countries', J Antimicrob Chemother, Vol. 65(9), pp. 2037-2040.kari.grave@ema.europa.eu
Herold R., Saint-Raymond A., 'Preamble may not improve consent and assent process', Ped Blood Cancer, Vol. 56(2), p. 327.ralf.herold@ema.europa.eu
Isaac M., Koch A., 'The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia', Eur Neuropsychopharmacol, Vol. 20(3), pp. 139-145.maria.isaac@ema.europa.eu
Jablonski T., 'Pharmaceuticals: End of the transitional period for traditional herbal medicinal products coming soon', Eur J Risk Regulation, Vol. 2, pp. 156-159.-
Liberti L., Breckenridge A., Eichler H. G., Peterson R., McAuslane N., Walker S., 'Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process', Clin Pharmacol Ther, Vol. 87(1), 27-31.lliberti@cmr.org
Mackay D., Kriz N., 'Current challenges in viral safety and extraneous agent testing', Biologicals, Vol. 38(3), pp. 335-337.david.mackay@ema.europa.eu
Maignen F., Hauben M., Tsintis P., 'Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation', Drug Saf, Vol. 33(5), pp. 417-434.francois.maignen@ema.europa.eu
Matheis K., Laurie D., Andriamandroso C., Arber N., Badimon L., Benain X., Bendjama K., Clavier I., Colman P., Firat H., Goepfert J., Hall S., Joos T., Kraus S., Kretschmer A., Merz M., Padro T., Planatscher H., Rossi A., Schneiderhan-Marra N., Schuppe-Koistinen I., Thomann P., Vidal J. M., Molac B., 'A generic operational strategy to qualify translational safety biomarkers', Drug Discov Today, Vol. 16(13-14), pp. 600-608.beatrice.molac@firalis.com
Regnstrom J., Koenig F., Aronsson B., Reimer T., Svendsen K., Tsigkos S., Flamion B., Eichler H. G., Vamvakas S., 'Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency', Eur J Clin Pharmacol, Vol. 66(1), pp. 39-48.jan.regnstrom@ema.europa.eu
Saint-Raymond A., 'EMEA sees benefits for children', Applied Clinical Trials Online, February 2010.agnes.saint-raymond@ema.europa.eu
Saint-Raymond A., 'Regulatory aspects of drug development in children: change and resistance to change', Expert Rev Clin Pharmacol, Vol. 3(5), pp. 593-595.agnes.saint-raymond@ema.europa.eu
Saint-Raymond A., Hill S., Martines J., Bahl R., Fontaine O., Bero L., 'CONSORT 2010', Lancet, Vol. 376(9737), pp. 229-230.agnes.saint-raymond@ema.europa.eu
Seigneuret N., 'The paediatric regulation: three years on', Regulatory Rapporteur, Vol. 7(6), pp. 5-9.-
Silva-Lima B., Due Theilade-Thomsen M., Carleer J., Vidal J. M., Tomasi P., Saint-Raymond A., 'Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European Medicines Agency workshop on juvenile animal testing for nonclinical assessors', Birth Defects Res B Dev Reprod Toxicol, Vol. 89(6), pp. 467-473.agnes.saint-raymond@ema.europa.eu
Sistare F. D., Dieterle F., Troth S., Holder D.J., Gerhold D., Andrews-Cleavenger D., Baer W., Betton G., Bounous D., Carl K., Collins N., Goering P., Goodsaid F., Gu Y. Z., Guilpin V., Harpur E., Hassan A., Jacobson-Kram D., Kasper P., Laurie D., Lima B. S., Maciulaitis R., Mattes W., Maurer G., Obert L. A., Ozer J., Papaluca-Amati M., Phillips J. A., Pinches M., Schipper M. J., Thompson K. L., Vamvakas S., Vidal J. M., Vonderscher J., Walker E., Webb C., Yu Y., 'Towards consensus practices to qualify safety biomarkers for use in early drug development', Nat Biotechnol, Vol. 28(5), pp. 446–454.frank_sistare@merck.com
Spina A. 'European networks in the regulation of biotechnologies', Eur Law Rev, Vol. 35(2), pp. 197-213.-
Stoyanova-Beninska V. V., Wohlfarth T,. Isaac M., Kalverdijk L. J., van den Berg H., Gispen-de Wied C., 'The EU paediatric regulation: effects on paediatric psychopharmacology in Europe', Eur Neuropsychopharmacol, Vol. 21(8), pp. 565-570.v.stoyanova@cbg-meb.nl
Surh L. C., Pacanowski M. A., Haga S. B., Hobbs S., Lesko L. J., Gottlieb S., Papaluca-Amati M., Patterson S. D., Hughes A. R., Kim M. J., Close S. L., Mosteller M., Zineh I., Dechairo B., Cohen N. A., 'Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs', Pharmacogenomics, Vol. 11(12), pp. 1637-1647.lcsurh@gmail.com
Tomasi P., 'In search of safe and effective medicines', European Pharmaceutical Contractor, winter 2010, pp. 46-49.paolo.tomasi@ema.europa.eu
Vidal J. M., Kawabata T. T., Thorpe R., Silva-Lima B., Cederbrant K., Poole S., Mueller-Berghaus J., Pallardy M., van der Laan J. W., 'In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency workshop', Cytokine, Vol. 51(2), pp. 213-215.jean-marc.vidal@ema.europa.eu

 

2009

Back to top

PublicationCorresponding author
Borg J. J., Robert J. L., Wade G., Aislaitner D., Pirożynski M., Abadie E., Salmonson T., Vella Bonanno P., 'Where is industry getting it wrong? A review of quality concerns raised at day 120 by the Committee for Medicinal Products for Human Use during European centralised marketing authorisation submissions for chemical entity medicinal products', J Pharm Pharm Sci, Vol. 12(2), pp. 181-198.john-joseph.borg@gov.mt
Brasseur D., Pons G., Sain-Raymond A., 'Le règlement européen de &quotmeilleurs médicaments pour les enfants en Europe&quot. Une chance pour la recherche et les soins en pédiatrie?' In: Delfosse M. L., Parizeau M. H., Amman J. P. La recherche clinique avec les enfants: à la croisée de l'éthique et du droit. Belgium, France, Quebec: Editions Anthemis, pp. 51-66.-
Broich K., 'Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants', Eur Neuropsychopharmacol, Vol. 19(5), pp. 305-308.-
Celis P., Miglicacio G., Pedone E., Petracek J., Pinheiro M. H., Salmikangas P., Schneider C. K., 'Advanced therapies: Regulatory principles and practice', Regulatory Rapporteur, Vol. 6, pp. 12-16.-
Celis P., Pedone E., 'The Committee for Advanced Therapies at the European Medicines Agency and the advanced therapies certification procedure', Drug Development, Vol. 4, pp. 64-67.patrick.celis@ema.europa.eu
Eichler H. G., Abadie E., Raine J. M., Salmonson T., 'Safe drugs and the cost of good intentions', N Engl J Med, Vol. 360(14), pp. 1378-1380.-
Eichler I., Saint-Raymond A., 'The EU paediatric regulation: the way forward or a barrier to progress?', RAJ Pharma, Vol. 20, pp. 347-348.-
Fanciulli G., Tomasi P. A., Delitala A. P., Delitala G., 'Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans', Exp Clin Endocrinol Diabetes, Vol. 117(9), pp. 460-462.gfanciu@uniss.it
Giezen T. J., Mantel-Teeuwisse A. K., Strauss S. M. J. M., Egberts T. C. G., Blackburn S., Persson I., Leufkens H. G. M., 'Evaluation of post-authorization safety studies in the first cohort of EU risk management plans at time of regulatory approval', Drug Saf, Vol. 32(12), pp. 1175-1187.a.k.mantel@uu.nl
Goedecke T., Brosch S., Arlett P., 'EudraVigilance - the common EU database to support pharmacovigilance activities', Regulatory Rapporteur, Vol. 6(2), pp. 6-11.-
Grein K., 'Pharmacovigilance and the European Medicines Agency: conduct of pharmacovigilance activities', In: Woodward, K. N. (ed.) Veterinary pharmacovigilance: adverse reactions to veterinary medicinal products. Wiley-Blackwell.-
Jekerle V., Schröder C., Pedone E., 'Legal basis of the advanced therapies regulation', Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, Vol. 53(1), pp. 4-8.veronika.jekerle@ema.europa.eu
Ludolph A. C., Kassubek J., Landwehrmeyer B. G., Mandelkow E., Mandelkow E. M., Burn D. J., Caparros-Lefebvre D., Frey K. A., de Yebenes J. G., Gasser T., Heutink P., Höglinger G., Jamrozik Z., Jellinger K. A., Kazantsev A., Kretzschmar H., Lang A. E., Litvan I., Lucas J. J., McGeer P. L., Melquist S., Oertel W., Otto M., Paviour D., Reum T., Saint-Raymond A., Steele J. C., Tolnay M., Tumani H., van Swieten J. C., Vanier M. T., Vonsattel J. P., Wagner S., Wszolek Z. K., Reisensburg Working Group for Tauopathies With Parkinsonism, 'Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options', Eur J Neurol, Vol. 16(3), pp. 297-309.albert.ludolph@rku.de
Manolis E., Pons G., 'Proposals for model-based paediatric medicinal development within the current European Union regulatory framework', Br J Clin Pharmacol, Vol. 68(4), pp. 493–501.efthymios.manolis@ema.europa.eu
Novelli G., Borgiani P., Ciccacci C., Di Daniele N., Sirugo G., Papaluca Amati M., 'Pharmacogenomics: role in medicines approval and clinical use', Public Health Genomics, Vol. 13(5), pp. 284-291.novelli@med.uniroma2.it
Saint-Raymond A., 'Médicaments pédiatriques et recherche : un équilibre fragile à trouver entre risques et bénéfices', In: Delfosse M. L., Parizeau M. H., Amman J.P. La recherche clinique avec les enfants: à la croisée de l'éthique et du droit. Belgium, France, Quebec: Editions Anthemis.-
Saint-Raymond A., Seigneuret N., 'The European paediatric initiative: 1 year of experience', Paediatr Drugs, Vol. 11(1), pp. 9-10.paediatrics@ema.europa.eu
Saint-Raymond A., Sweeney F., 'Clinical trials in developing countries: risk or opportunity?' Future Med Chem, Vol. 1(7), pp. 1193-1195.agnes.saint-raymond@emea.europa.eu
Schneider C. K., Papaluca M., Kurki P., 'A European perspective on immunogenicity evaluation', Nat Biotechnol, Vol. 27(6), pp. 507-508.schci@pei.de
Scientific Advisory Group on Antimicrobials of the Committee for Medicinal Products for Veterinary Use, 'Reflection paper on the use of third and fourth generation cephalosporins in food producing animals in the European Union: development of resistance and impact on human and animal health', J Vet Pharmacol Ther, Vol. 32(6), pp. 515-533.christina.greko@sva.se
Shah R. R., Saint Raymond A., 'Regulation of human medicinal products in the European Union', In: Griffin J. P. The textbook of pharmaceutical medicine. 6th ed. London: BMJ Books, pp. 444-499.-
Shivji R., Purves J., Celis P., 'European Medicines Agency: influenza pandemic preparedness'. Risk Wise: Epidemics, ISBN: 0-9536140-6-9, pp. 36-39.-

 

2008

Back to top

PublicationCorresponding author
Blackburn S., 'The European Network of Centres in Pharmacoepidemiology and Pharmacovigilance', PRM Newsletter, Vol. 0, pp. 5-6.-
Blind E., 'Twenty years of progress with parathyroid hormone (PTH): from specialized and &quotdifficult&quot measurement to common laboratory parameter and treatment option in osteoporosis', Clin Lab, Vol. 54, pp. 439-449.eberhard.blind@emea.europa.eu
De Clercq K., Goris N., Barnett P. V., Mackay D. K., 'FMD vaccines: reflections on quality aspects for applicability in European disease control policy', Transbound Emerg Dis, Vol. 55(1), pp. 46-56.kris.de.clercq@var.fgov.be
De Clercq K., Goris N., Barnett P. V., Mackay D. K., 'The importance of quality assurance/quality control of diagnostics to increase the confidence in global foot-and-mouth disease control', Transbound Emerg Dis, Vol. 55(1), pp. 35-45.kris.de.clercq@var.fgov.be
Eichler H. G., Pignatti F., Flamion B., Leufkens H., Breckenridge A., 'Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma', Nat Rev Drug Discov, Vol. 7(10), pp. 818-826.hans-georg.eichler@ema.europa.eu
Hauben M., Vogel U., Maignen F., 'Number needed to detect: nuances in the use of a simple and intuitive signal detection metric', Pharm Med, Vol. 22(1), pp. 13-22.manfred.hauben@pfizer.com
Llinares J., 'Orphan designation in the EU: an overview and key achivements', Regulatory Rapporteur, November 2008, pp. 5-9.-
Neugebauer B., Drai C., Haase M., Hilger A., Keller-Stanislawski B., Laitinen-Parkkonen P., Mentzer D., Rasmussen C., Ratignier C., Seitz R., 'Factor VIII products and inhibitor development: concepts for revision of European regulatory guidelines', Haemophilia, Vol. 14(1), pp. 142-144.brigitte.neugebauer@ema.europa.eu
Ormarsdottir S., Reginster J. Y., Abadie E., 'European regulatory perspectives for innovative therapies', Osteoporos Int, Vol. 19(6), pp. 725-731.jyreginster@ulg.ac.be

 

2007

Back to top

PublicationCorresponding author
Grein K., Papadopoulos O., Tollis M., 'Safe use of vaccines and vaccine compliance with food safety requirements', Rev Sci Tech, Vol. 26(2), pp. 339-350.-
Mackay D., 'Authorisation within the European Union of vaccines against antigenically variable viruses responsible for major epizootic diseases', Rev Sci Tech, Vol. 26(2), pp. 421-428.david.mackay@emea.europa.eu

How useful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings

Related information